Trial Profile
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Cefepime/enmetazobactam-Allecra-Therapeutics (Primary) ; Piperacillin/tazobactam
- Indications Pyelonephritis; Urinary tract infections
- Focus Registrational; Therapeutic Use
- Acronyms ALLIUM
- Sponsors Allecra Therapeutics
- 15 Jun 2024 According to an ADVANZ PHARMA media release, the EC granted a marketing authorization for EXBLIFEP,for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis; hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP); and bacteraemia. EXBLIFEP will be marketed in the European Union, the United Kingdom, Switzerland, and Norway by ADVANZ PHARMA under a license and supply agreement closed with Allecra in 2022.
- 27 Feb 2024 According to an Allecra Therapeutics media release, the company has received a five-year marketing exclusivity extension from the FDA as part of the Generating Antibiotic Incentives Now Act (GAIN Act).
- 27 Feb 2024 According to an Allecra Therapeutics media release, the U.S. Food and Drug Administration (FDA) has approved EXBLIFEP (cefepime/enmetazobactam), as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.